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Chronic liver disease and hepatocellular carcinoma are some of the leading causes of death in the 
United States, resulting in a number of annual deaths that has only increased over the past 
several decades. A vast proportion of these liver-related deaths is due to chronic hepatitis B 
infection, which currently affects approximately 1.2 million people in the US. However, the 
hepatitis B virus does not affect every racial group in the United States equally: Asian Americans 
experience a disproportionately high prevalence of HBV infection. In fact, even though the 
APIA community comprises only 4% of the US population, they account for approximately 60% 
of the 1.2-2 million individuals affected with chronic hepatitis B in the US. This striking racial 
demographic of HBV-infected individuals is due to a myriad of biological and cultural factors 
such as emigration from regions with high HBsAg prevalence, a high rate of HBV vertical 
transmission from mother to child, and suboptimal HBV screening and management among 
immigrants and non-native English speakers. This paper proposes a two-part study, which 
utilizes surveys distributed to patients and health providers to create a free clinic event that will 
model optimal HBV screening and treatment strategies for Asian immigrants. From this study, 
we hope to implement changes in healthcare for Asian immigrants that will remedy cultural 
barriers and the disproportionate prevalence of HBV in APIA communities, in order to 
ultimately lower the overall rate of liver-related death in the US.   
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INTRODUCTION 
The Epidemiology of Liver Disease: liver cirrhosis, HCC, Hepatitis B and C 
Chronic liver disease and liver cirrhosis are two of the leading causes of death in the 
United States, contributing to approximately 45,000 annual deaths in the country (Center for 
Disease Control & Prevention, 2020), and 2 million deaths annually worldwide (Asrani et al., 
2019). These deaths are a result from both complications due to decompensated liver cirrhosis 
and viral hepatitis-related hepatocellular carcinoma (HCC). Liver disease can be caused by viral 
infection, immune system abnormalities, vertical transmission and other genetic factors, 
excessive alcohol consumption, and metabolic disease. In the United States, the most common 
causes of viral hepatitis are hepatitis B and C viruses, which are known to lead to the formation 
of liver cirrhosis and HCC. While information on virally transmitted liver diseases needs to be 
more widespread across the country, hepatitis B and C viruses do not affect all racial groups 
across the US equally -- immigrants from countries in Asia and sub-Saharan Africa are 
significantly more likely to be infected with hepatitis B than other racial groups in the US 
(Figure 1), with HBV prevalence in Asian subgroups ranging from 9% to 25% (Li et al., 2018).  
 
Figure 1. World map of countries with high rates of positive HBsAg, a serologic indicator for 
acute or chronic HBV infection (CDC, 2013).  
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The Epidemiology of Hepatitis C and Disease Progression 
 
Hepatitis C infection is the second most likely viral infection to cause liver cirrhosis and 
hepatocellular carcinoma. Of the world’s population, approximately 3% are infected with 
hepatitis C virus (Vescovo et al., 2016). The most common forms of hepatitis C transmission is 
through intravenous drug use in developed countries, while in developing countries, the most 
common forms of viral transmission are via contaminated instruments during invasive 
procedures or injection-based therapies (Morozov and Lagaye 2018). When acute hepatitis C 
infection goes untreated, this often develops into chronic hepatitis C (CHC), which can then 
result in inflammatory lesions in the liver known as hepatic steatosis, progressive fibrosis, 
compensated and decompensated cirrhosis, and hepatocellular carcinoma. Of the patients that 
develop hepatic steatosis and liver fibrosis, 10-20% of these patients’ liver disease develops into 
liver cirrhosis (Figure 2). Of these individuals, 1-5% eventually develop HCC, which requires 
treatments such as transarterial chemoembolization, chemotherapy, liver ablation, and, in most 
serious cases, liver transplantation. Progression of the virus is made more severe by other 
cofactors such as excessive alcohol consumption and metabolic liver disease. 
 
Figure 2. The progression of HCV infection, outlining the progression from a healthy liver to 
liver cirrhosis and liver cancer (Vescovo et al., 2016).  
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Epidemiology of Hepatitis B 
Although HCV infection continues to be a problem globally, compared to hepatitis C 
virus, hepatitis B is more transmissible and more deadly. At least 240 million people are affected 
by chronic hepatitis B infection (Dandri and Peterson, 2016), 60% of liver cancer diagnoses are 
due to cases of chronic hepatitis B, and 15-25% of those with inadequately screened and 
suboptimally treated  hepatitis B will die prematurely from liver cirrhosis, liver failure, or 
hepatocellular carcinoma (Hepatitis B Foundation, 2019).  
Furthermore, the molecular biology of the hepatitis B virus is less understood than that of 
the hepatitis C virus (HCV). As a result, complete eradication of HCV in 12-24 weeks is possible 
through antiviral medication, while HBV treatment requires life-long antiviral treatment that 
does not cure the infection or eradicate the virus, but greatly minimizes the risk of developing 
potentially fatal liver cirrhosis or HCC. In contrast to HCV, chronic hepatitis B infection can 
develop into hepatocellular carcinoma in the absence of liver cirrhosis, potentially making the 
virus more lethal due to fewer cirrhosis-related symptoms such as ascites, hepatic 
encephalopathy, and variceal bleeding, which can typically serve as a warning to start immediate 
treatment before the formation of HCC (Shim et al., 2017). In addition to these key differences 
between hepatitis B and C, HBV is more transmissible and causes more annual cases of cancer 
and death than hepatitis C. In total, the higher transmissibility of HBV and its ability to result in 
the formation of HCC in the absence of cirrhosis overall make the virus more deadly in 
comparison to HCV. Given the APIA population’s higher risk for HBV infection, it is essential 
to address HBV infection and liver disease as an endemic within the Asian community in order 
to decrease rates of liver-related mortality.   
Trinh 6 
Molecular Biology and Infection Mechanism of Hepatitis B Virus 
The hepatitis B virus is also unique in its molecular biology and structure: its virion 
contains a nucleocapsid of the HBcAg core protein, and the genome within the nucleocapsid 
forms a relaxed circular partially double-stranded DNA, linked to the viral polymerase (Dandri 
and Petersen, 2016). When the virus reaches the host, it sheds high rates of subviral particles that 
bear both small and large HBV surface antigens (HBsAg). Serum levels in individuals infected 
with chronic hepatitis B can have HBsAg levels of up to 400 ​μg/mL (Mohebbi et al., 2018). 
Although only approximately 1 of 10,000 subviral particles are infectious, those infected with 
chronic hepatitis B who also carry HBsAg have at 25-37% higher risk for later developing HCC 
(Kondo et al., 2013). The biological function of the many non-infectious subviral particles is still 
unknown, although studies have suggested that they may have a role in suppressing the host 
immune response, and in neutralizing antibodies produced by the host in response to high levels 
of HBsAg (Dandri and Petersen, 2016). In addition to vertical transmission from mother to child, 
the hepatitis B virus is transmitted through percutaneous exposure to other infected body fluids. 
The virus travels via the bloodstream to the liver, where it enters the hepatocyte nucleus via 
endocytosis. Upon entry and interaction with the nuclear pore complexes, the mature capsids of 
the virus disintegrate, allowing partially double-stranded DNA to enter the nucleus and to be 
converted to cccDNA (Dandri and Petersen, 2016). The cccDNA serves as the template for the 
transcription of viral mRNA, which is then sent out of the nucleus into the cytoplasm for protein 
synthesis ​(Figure 3).​ This translation of viral mRNA in the cytoplasm is followed by protein 
packaging and synthesis of plus and minus-strand DNA. Finally, the new nucleocapsids are 




Figure 3. Portrayal of the HBV life cycle and interaction with host cell (Tong et al., 2013).  
 
Common Methods for Prevention and Treatment of Chronic Hepatitis B 
HBV treatments can be divided into the categories of either prevention or catch-up. 
Global pre-infection vaccination has proven to be the most effective and cost-efficient method 
for reducing the threat of HBV infection. Since 1991, the World Health Organization (WHO) has 
recommended that all countries incorporate the HBV vaccine into their national immunization 
programs (Das et al., 2019). Infant immunization is the most effective and now most common 
form of prevention, and the vaccination is delivered on day 0, month 1, and month 6 of infancy. 
Pre-infection vaccinations are intended to boost the immune system of the host, which eradicates 
any HBV surface antigen in the individual and keeps the replication of introduced HBV under 
control.  
Catch-up strategies for HBV treatment are of equal importance especially for individuals 
born outside the United States and those born after the HBV vaccination was widely used. 
Extensive research for HBV cures is still underway. Two treatments for chronic hepatitis B have 
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been approved for public use: interferon treatment (IFN) and nucleos(t)ide analogs (NAs). These 
treatments unfortunately do not eliminate the virus in those diagnosed with CHB, but are 
successful in suppressing continued HBV replication and decreasing risk for fatal CHB 
symptoms such as liver cirrhosis, liver failure, and hepatocellular carcinoma development (Lok, 
2019). Commonly used treatments for chronic hepatitis B include interferons such as interferon 
alpha-2b and PEGylated interferon, and the more common antiviral nucleos(t)ide analog 
medications entecavir and tenofovir.  
The diagnosis criteria for acute or chronic HBV infection include liver enzyme tests, lab 
tests for the presence of the alpha-fetoprotein tumor marker, lab tests for the presence of HBV 
serological markers (Figure 4, 5), and screening via CT or MRI. 
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Figure 4. An outline of the interpretations of various serologic test results: how HBsAg, 
anti-HBc, IgM anti-HBc, anti-HBs results indicate acute or chronic HBV infection along with 
HBV vaccination history (CDC, 2013).  
 
Figure 5. Definitions and implications for the presence of HBV serological markers HbsAg, 
anti-HBs, anti-HBc. Derived from the CDC article “Testing Asian Americans and Pacific 
Islanders for Hepatitis B.”   
HBsAg:​ Hepatitis B surface antigen. Positive HBsAg indicates that the individual is infectious 
with acute or chronic HBV. 
anti-HBs:​ Hepatitis B surface antibody. Generally indicates recovery and/or immunity from 
HBV infection, and develops in those successfully vaccinated against hepatitis B.  
anti-HBc:​ Total hepatitis B core antibody. Typically appears at the onset of symptoms and 
persists for life, including in treated individuals. Indicates previous or ongoing HBV infection. 
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Genetic Factors for Chronic Hepatitis B 
While modes of chronic hepatitis B transmission such as via bodily fluids of infected 
individuals and vertical transmission from mother to child is well known, other genetic factors 
that contribute to hepatitis B susceptibility are still being widely researched. Currently, there are 
ten known genotypes of the hepatitis B virus, with 4-12 subgenotypes within each. HBV 
genotypes and subgenotypes are known to have different clinical outcomes, and genotype 
prevalence and distribution are dependent on ethno-geographical location (Gao et al., 2019). 
Several studies highlighting the differences between HBV genotypes found that the effects of 
HBV genotype B are less severe than those of genotype C, with overall slower liver damage and 
disease progression via earlier HBeAg seroconversion, higher HBsAg seroclearance rates, and 
lower HBV DNA levels, implying that HBV genotype C may have stronger pathogenicity (Tian 
and Jia, 2016). While the ethno-geographical distributions of HBV genotypes  are not as 
distinguished within the United States, there are clearer distributions based on international 
geographic locations. HBV genotype F is most prevalent in various South American countries, 
while genotypes A and E have high prevalence in West Africa, and genotypes A and D have 




Figure 6. Geographic distributions of HBV genotypes by country. The figure excludes 
inter-genotype recombinant viruses and co-infections with greater than one HBV genotype 
(Velkov et al., 2018).  
 
Studies have found that treatment and prevention effectiveness can vary across different 
HBV genotypes, suggesting that detailed knowledge of HBV genotype can increase the 
effectiveness of HBV replication suppression. In total, regarding treatment, studies suggest that 
optimizing CHB treatment depends on geographic region, accessibility to care, timing of 
intervention before progression of liver-related symptoms, and HBV genotype. With these 
factors in mind, physicians can treat and prevent CHB with highest efficacy and ultimately 
decrease the number of global deaths resulting from CHB. As indicated by Figure 6, the HBV 
genotype distribution across the US is less understood than in other countries, emphasizing the 
need to record the genotype and subgenotype in HBV patients more consistently, ultimately 
offering a better understanding of the effects of racial and ethnic background on HBV infection 
rates.  
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Epidemiology of HBV in Asian Immigrants in the US 
Asian Americans in the United States are especially at risk for having chronic hepatitis B. 
Although Asian Americans make up only 4% of the US population, they comprise approximately 
60% of the 1.2-2 million individuals infected with CHB in the US. Additionally, only 1 in 1,000 
non-Hispanic Whites are chronically infected with hepatitis B compared to 1 in 12 Asian 
Americans, indicating one of the greatest racial health disparities in the United States (Stanford 
Medicine Asian Liver Center, 2020). There are several proposed reasons for this striking 
disparity: high CHB prevalence has been an issue in East Asian countries due to a history of 
improper sterilization or disposal of needles and other medical supplies over previous decades. 
Since treatment that drives successful eradication of the virus does not yet exist, and because the 
rate of vertical transmission of HBV from mother to child is particularly high (1-28%) compared 
to other chronic diseases including HCV, the HBV endemic persists in East Asian countries, 
resulting in a high prevalence of HBV infection in both Asian immigrants and the children of 
Asian immigrants (Mavilia and Wu, 2017). While the prevalence of CHB infection is relatively 
low in the United States as a whole, increasing rates of immigration from East Asia, a region 
with a higher prevalence of positive hepatitis B surface antigen, have resulted in health 
disparities among Asian American populations (Chen Jr and Dang, 2015).  
Liver-Related Death in Asian Americans  
While the hepatitis B virus itself does not cause death in infected individuals, untreated 
HBV infection can lead to fatal liver impairment, via development of liver cirrhosis or 
hepatocellular carcinoma. As already stated, HBV infection can lead to the formation of HCC 
even in the absence of liver cirrhosis. Because of the disparately high prevalence of chronic 
hepatitis B among Asian Americans, they also have the highest incidence of hepatocellular 
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carcinoma compared to other racial or ethnic groups across the United States (Table 1). In fact, 
Asian Americans are the only racial or ethnic group in the US whose leading cause of 
cancer-related death is liver cancer (Sarpel et al., 2018). Because Asian Americans make up a 
quickly growing demographic within the US, and because many Asian immigrants have not been 
routinely vaccinated for HBV, the prevalence of HCC development as a result of chronic 
hepatitis B infection remains a growing problem in the US. Studies have shown that Asians have 
received more liver transplantations due to hepatocellular carcinoma development than other 
racial groups in the US (Kemmer, 2011).  
 
Table 1. Etiology of Liver Disease in Liver Transplantation Recipients (Kemmer, 2011). Asians 
received significantly more liver transplantation procedures due to liver complications from 
HCC. Additionally, Asians received significantly more liver transplantations due to HBV 
infection than White, Hispanic, or Black populations.  
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What Are the Known Disparities in HBV Treatment in Asian Americans? 
There are several factors that contribute to the growing racial health disparity between 
Asians and non-Asians in the United States. Studies have shown that Asian immigrants and 
children of Asian immigrants are less likely to have health insurance coverage than non-Hispanic 
white individuals. In addition, even those that do have health insurance are less likely to receive 
high-quality healthcare compared to non-Hispanic Whites (Clough et al., 2013). The disparities 
in health insurance coverage and quality in healthcare are primarily due to language barriers 
between health providers and their patients, cultural differences regarding approaches to health, 
lack of access to health services, and racial discrimination within the healthcare system.  
Throughout history, US immigrants and children of immigrants have had a high 
likelihood of being uninsured, and in 2012, it was estimated that up to 6 million immigrants 
could benefit from universal health coverage. Provisions to the 2010 Patient Protection and 
Affordable Care Act were made in 2013, and subsequent changes in rates in insurance coverage 
followed in 2016. While these changes somewhat ameliorated the low coverage for Asian 
immigrants by reducing the waiting period required for US residence prior to qualifying for 
health insurance, there still remains a significant disparity in medical care that Asian Americans 
receive compared to non-Hispanic White Americans.  
The racial disparities in healthcare quality are only further driven by differences in 
socioeconomic status within the Asian American community. Millions of more individuals have 
received health insurance coverage under the Affordable Care Act, which allows low-income 
individuals, which equated to those receiving an annual income of $17,236 or less in 2019, to be 
eligible for Medicaid (Garfield and Orgera, 2020). Fourteen states in the US failed to participate 
in this expansion of Medicaid eligibility, making the income cutoff point that qualifies for 
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eligibility of Medicaid much lower in these states. Although the Medicaid eligibility expansion 
has resulted in significantly more health insurance coverage in communities of color across the 
country, there is still a significant coverage gap which represents those who are not eligible for 
Medicaid under the Affordable Care Act, yet are still unable to afford coverage through private 
health insurance companies (Figure 6).  
 
Figure 7. Highlights populations of people that make up the “Coverage Gap,” or those whose 
income is above the upper limit of Medicaid eligibility, but below the lower limit for other 
private means of health insurance (Garfield and Orgera 2020).  
 
The national health insurance coverage gap in addition to lower quality healthcare faced 
by US immigrants is especially alarming for Asian immigrants in the US who suffer from HBV 
infection. Despite the fact that the CDC recommends that anyone born or with one parent born in 
any Asian country, any Pacific Island, and any other countries with moderate to high rates of 
hepatitis B (Figure 1) should be tested for Hepatitis B with an HBsAg test (CDC, 2013), many 
primary care physicians are either unaware of or do not practice this recommendation.  
Studies have shown that physician adherence to the American Association for the Study 
of Liver Disease (AASLD) guidelines for management of HBV infection has been suboptimal 
across the country, ultimately affecting communities of Asian immigrants whose undiagnosed 
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HBV infections progress past the stage at which treatment is most effective. There were several 
factors significantly associated with more effective HBV screening, such as provider ability to 
speak an Asian language and having more than 25% of Asian patients in practice (Mukhtar and 
Kathpalia et al., 2017). These findings suggest that there is significant room for improvement in 
HBV management among health providers, especially among those that serve a minimal Asian 
demographic.  
In addition to the evident disparity in HBV management knowledge among health 
providers, racial discrimination and cultural differences within the healthcare system are critical 
barriers for Asian immigrants seeking healthcare. Non-native English speakers and people of 
color have a pattern of choosing non-white physicians due to implicit racial bias among 
healthcare professionals and resulting increased comfort during their appointments (Hall et al., 
2015). Though, many patients, especially those in rural areas, are not given the privilege of 
choosing  health providers that share parts of their cultural background. Implicit racial bias and 
cultural differences between provider and patient lead to gaps in communication and health 
education, ultimately contributing to the already existing racial disparity in HBV infection in the 
US.  
There are several primary factors that contribute to the racial disparity in hepatitis B 
prevalence among Asian and non-Asian communities in the US: these factors include differences 
in health education due to a lack of English fluency, differences in health provider management 
of HBV infection, genotypic differences in HBV depending on country of birth, and variance in 
patient compliance with prescribed treatment. The objective of this study is to highlight the 
significant change in patient outcome that could result from alterations in general screening 
protocols in addition to increased efforts to prioritize cultural competence among health 
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providers. This paper proposes a study consisting of a patient survey, provider survey, and 
long-term longitudinal study which utilizes genetic testing for HBV genotype to target treatment. 
The first survey, directed toward older individuals in the APIA community in the Orange County 
area, is intended to indicate a disparity in knowledge regarding the dangers of HBV infection and 
liver disease within the Asian American community. The second survey, which will be 
distributed to various health providers in both rural and urban regions of the United States, will 
assess the proposed phenomenon that providers who do not speak an Asian language or serve a 
significant proportion Asian patients are less likely to provide proper management of HBV 
infection. The results of these surveys will be consolidated to create a health fair event which 
will attempt to address both the cultural and clinical disparities found in the surveys, by 
recruiting multilingual health providers of Asian descent, offering free liver screenings and 
hepatologist referrals, and providing free educational seminars regarding the importance of HBV 
management in the APIA community. These particular components of the health fair are 
intended to increase cultural competence between provider and patient, maximize patient 
compliance with their HBV treatment, and improve health education among Asian immigrants. 
The results of this study could lead to the development of more specific treatment plans for 
Asian immigrants in the US at high risk for CHB, ultimately decreasing the rate of liver-related 
mortality in APIA communities. With the results of the surveys and longitudinal study, we hope 
to determine whether or not the current racial disparity in HBV prevalence can be improved with 
increased health education targeted toward immigrants, improved cultural competence and racial 
bias training among health providers, and more clinical opportunities for free healthcare for 
immigrant communities.  
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METHODS 
HBV Awareness Survey 
In order to assess the rates of potentially untreated HBV infections and the disparity in 
knowledge regarding HBV risk in the Asian American community, a survey will be conducted 
online and in person in areas frequented by individuals of Asian descent. Guidance for the survey 
questions will be provided by healthcare and governmental organizations that have done 
previous work on health disparities within the Asian American community, such as the Asian 
Liver Center, the San Francisco Hep B Free Campaign, and the AsianWeek Foundation. The 
surveys will be conducted primarily through SurveyMonkey.com, though our results will also 
include questionnaire answers from telephone surveys and street intercept surveys. Parts of the 
survey will include ideas from a study performed by the San Francisco Hep B Free Campaign 
(Shiau et al., 2011). Those surveyed will be individuals of Asian descent that are 40 years old or 
older, including participants born both in the US and in countries outside the US. This age group 
was chosen because it comprises a higher percentage of Asian individuals born outside the US: 
this demographic has a higher risk of hepatitis B infection, and is potentially less likely to have 
received the HBV vaccine. The identity-based demographics collected through the survey will 
include age, ethnicity, place of birth, annual income, and health insurance membership. The 
responses of any individuals with a unique interest and therefore thorough knowledge of 
hepatitis risks and treatment will be excluded from the study. The survey will offer translations 
from English to Vietnamese, Chinese, and Korean if needed.   
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Figure 8. List of survey questions addressing the medical needs of hepatitis B awareness among 
individuals of Asian descent 
 
Figure 9. List of survey questions for primary care providers, assessing the prevalence of 
hepatitis B screening for at risk populations  
Identity information: 
Age, sex, place of birth, languages spoken (and native language) 
Annual income and health insurance coverage 
___ 
Have you ever heard of a medical condition called hepatitis B? 
How can someone prevent getting hepatitis B, and how can they prevent giving it to others? 
Have you ever been tested for hepatitis B?  
     What made you get tested for hepatitis B? 
     How long ago did you get tested? 
     If you have not been tested, why not? 
Do you know someone infected with hepatitis B? 
Have you heard about hepatitis B risk within your community? 
___ 
Do you feel like you can easily access medical care if needed? 
What race/ethnicity is your medical provider? 
Have you ever faced a language barrier with your medical provider? 
     Do you think you would benefit from a translator during your medical appointments? 
 
**Some questions derived from study by Shiau et al., 2011. 
Identity information: 
Racial identity of physician, languages spoken 
What is the racial demographic of your patients? 
What percentage of your patients do you screen for hepatitis B? 
Is hepatitis B screening part of your routine screening protocol? 
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The Health Fair -- A Longitudinal Study  
To assess whether adequate screening and early intervention makes a significant 
difference in Asian patient outcomes, a longitudinal study over sixteen years will be conducted 
that compares the outcomes of optimally screened individuals at risk for HBV infection with the 
current national statistic of HBV infections in Asian Americans. A free clinic event or “health 
fair”, modeled after that of the San Francisco Hep B Free Campaign, will be held in Orange 
County, CA for individuals at high risk for HBV infection. The health fair will be advertised to 
Asian patients at risk for HBV via posts on Facebook pages, TV advertisements on Vietnamese 
and Chinese TV channels, and radio stations with high rates of Asian listeners. The event will 
also be advertised with flyers (translated into Vietnamese, Mandarin, Cantonese, Cambodian, 
and Korean) that will be posted in areas frequented by older Asian individuals, and the waiting 
rooms of doctor’s offices.  
The health fair will offer several free services to patients in attendance with or without 
health insurance coverage. Services will include liver function blood tests, hepatitis B 
vaccinations for those not yet vaccinated or infected, and referrals to hepatology specialists for 
individuals with HBV infection or abnormal liver function results. Along with typical liver 
function lab tests, consenting attendees will undergo HBV serologic tests for HBsAg, anti-HBc, 
and anti-HBs* (Figure 5). For individuals infected with hepatitis B, their genotype and 
subgenotype will also be recorded, to optimize the form of treatment and to add to the existing 
database of hepatitis B genotype by geographic location (or country of birth). Multilingual 
providers or translators will also be available for any patient questions. 
A total of 5-6 physicians and other healthcare providers will comprise the health fair 
team. Their responsibilities will include running liver function labs, administering hepatitis B 
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vaccines, writing referrals to specializing hepatologists for infected individuals, and annual 
follow-ups with the primary care physicians and liver specialists of the health fair participants. In 
exchange for these free services, participating patients will be asked to consent to a non-invasive 
longitudinal study, in which their medical records will be checked every 4 years for 16 years by 
the health fair physician team (Figure 10).  
In addition to health services and screening, the fair will also include an educational 
aspect to spread awareness about the increased risk for hepatitis B in individuals of Asian 
descent. Several seminars will be offered to the patients in attendance: topics covered will 
include modes of hepatitis B prevention and the importance of the hepatitis B vaccine, common 
symptoms and forms of treatment for chronic HBV infection, and tools to navigate healthcare for 
non-English speakers. Although the health fair will be open to all individuals interested in 
learning more about hepatitis B and receiving free screening, the demographic is expected to 
consist of mostly older Asian immigrants with limited English proficiency, a population that 
often receives inadequate healthcare due to language barriers, social practice, cultural beliefs, 
and racial prejudice in the health industry.  
A follow up every four years will be led by the health care physician team with the 
primary care physicians and liver function specialists of the participating health fair patients. The 
following patient information will be collected:  
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Figure 10. Data to be collected every four years in patients being treated for HBV infection 
following the health fair. 
 
EXPECTED RESULTS 
HBV Awareness Among Asian Individuals 
Results from Part 1 of the patient survey are intended to indicate what aspects of hepatitis 
B are typically well-known among Asian individuals along with testing and screening adequacy 
among this population. Based on the results in other community-based studies such as those by 
Shiau et al and Chen Jr & Dang, it is expected that older Asian individuals will have a relative 
misunderstanding about the ways to successfully prevent hepatitis B infection. In addition, while 
we expect that most individuals will have heard about hepatitis B that many have either not been 
tested, or were tested at an older age (above 50 years old). Lastly, we also expect that the reasons 
for never having gotten tested for hepatitis B were due partly to cultural preferences, but mostly 
because their health provider did not mention hepatitis B, and the patient therefore never asked 
for a test.   
How many patients have received regular screening for liver function abnormalities? 
How many patients have positive HBsAg (if any)? 
How many patients with HBV infection are not receiving treatment? 
     What are the reasons for not receiving treatment (insurance denial, patient refusal, etc.) 
How many patients are on HBV treatment?  
     What form of treatment (interferon, nucleos(t)ide analogs -- tenofovir, entecavir, adefovir)? 
How many patients (if any) have developed hepatocellular carcinoma? 
     Has their HCC been effectively treated? 
Have there been any reported liver-related deaths? 
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Differences in HBV Management Among Health Providers 
The second portion of the patient survey is intended to point more directly toward the 
disparities in healthcare between Asians and non-Asians in the US, and significant results would 
offer insight as to how differences in healthcare accessibility has tangible effects in disease 
prevalence across different races. It is expected that older Asian immigrants will feel less access 
to their healthcare providers, due to language barriers or technical difficulties in the increasingly 
used Telehealth system. Additionally, we expect that many Asian immigrants whose native 
languages are not English are likely to have Asian doctors with similar ethnic backgrounds. 
While we expect that a significant proportion of older Asian patients will have bilingual doctors 
and/or doctors with translators, we also foresee that those with physicians that are purely 
English-speaking have faced language barriers with their providers, and feel that they would 
benefit from a translator or interpreter during their appointments.  
Health Fair -- Changes in Disease Progression and Patient Outcome  
The overall objective of the health fair study is to alter the typical pathway of Asian 
immigrants untreated for HBV infection (Figure 11) into one which intervenes HBV progression 
early and reduces the overall rate of liver-related death (Figure 12). Due to the evidence pointing 
to a disparity in medical service provided to older Asian immigrants (especially those without 
English fluency), we expect the health fair to have several hundred attendees. Of these attendees, 
our goal is to be able to track the results of 200 patients following the health fair for the 
longitudinal study. With this goal in mind, we expect 1-2 health fairs will be necessary to gather 
sufficient data. From the results of other studies that have outlined the importance of early 
screening for HBV such as those by Post et al., 2014 and Lok, 2019, we expect to see significant 
differences in health outcomes when comparing the patients who attended the health fair, and the 
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current HBV statistics among Asian American populations. Specifically, we expect to encounter 
a higher prevalence of positive HBsAg in the patients attending the health fair than the national 
statistic. We also believe that we will encounter a significant number of patients that have been 
living unknowingly with chronic HBV infection. We hope that during the four year check-ins we 
will find that more Asian patients than the national average are receiving adequate treatment for 
their chronic hepatitis B infection, and therefore fewer diagnoses for hepatocellular carcinoma.  
 
Figure 11. The pathway of Asian immigrants who go untreated for HBV infection, indicating 
that lack of adequate treatment can lead to the development of liver cirrhosis, HCC, and death.  
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We expect to find a high prevalence of HBV misinformation in older individuals of Asian 
descent. Immigrant populations not only face more difficulty accessing health-related 
information through informative posters and advertisements, but also are unable to advocate for 
themselves during appointments with their physicians as effectively as non-Hispanic white 
patients, leading to an apparent health disparity that has compounded over decades. Because of 
this, Asian patients continue to be informed of high health risks not necessarily by medical 
professionals but by friends and family, resulting in overall inadequate screening for diseases 
that have high prevalence in Asian immigrants and their descendants, such as hepatitis B.  
The intention of the survey for the general public is to gather the extent to which older 
Asian individuals are aware of their higher risk for hepatitis B, and whether they have received 
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the adequate information from health providers to protect themselves from infection or disease 
progression. From the survey answers we will consolidate the common misinformation and gaps 
in HBV knowledge in the APIA community to create an informational pamphlet to be distributed 
to older Asian individuals throughout Orange County. Although some organizations such as the 
San Francisco Hep B Free Campaign and the Asian Liver Center have been fairly successful in 
providing education on HBV prevention among higher risk individuals in the APIA community, 
we expect there to still be a need for further hepatitis awareness not only on the patient side, but 
on the health provider side as well. While of course the majority of health providers are 
well-educated in the dangers and means of prevention for HBV infection, studies have shown 
that health providers who do not typically serve communities at high risk for infection, such as 
individuals from certain countries in Asia and sub-Saharan Africa, do not screen for liver disease 
as much as necessary. In fact, factors such as the ability to speak an Asian language and having 
more than 25% of Asian patients in practice were significantly associated with differences in 
rates of HBV screening (Mukhtar and Kathpalia, 2017). Based on the results of these studies, we 
expect the results of the provider survey to reflect that Caucasian doctors, and other doctors who 
lack cultural connection to patients with ties to Asian and sub-Saharan African countries, screen 
for HBV significantly less than health providers who have exposure to high-risk communities. 
Additionally, we expect that providers that serve predominantly Caucasian patients to be less 
familiar with the AASLD guidelines for HBV management and liver cancer screening. Because 
of this disparity in knowledge, there may be a risk that Asian patients who see doctors with 
limited experience serving the APIA community may not be receiving adequate care for their 
HBV infection. Given the importance of early treatment intervention in liver disease progression, 
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these shortcomings in provider management may have widespread fatal consequences for APIA 
populations.  
While effective therapies are available for HCV cure and HBV suppression, challenges 
remain in screening and linkage to care and treatment, particularly for vulnerable populations 
both domestically and worldwide. The health fair study is intended to serve as an example for a 
population of APIA patients adequately screened and treated for HBV infection. The results of 
the longitudinal study will provide essential information to determine whether the liver health of 
the APIA community can be significantly improved with early HBV intervention. At the health 
fair we expect to find a higher prevalence of patients with positive HBsAg than the national 
average for APIA communities, which will add to the existing evidence that cases of chronic 
HBV infections in Asian communities are being under-diagnosed. Finding positive HBsAg in 
patients not yet diagnosed for chronic hepatitis B is essential, given that early treatment in 
individuals with HBsAg greatly decreases the risk of developing liver cirrhosis or hepatocellular 
carcinoma. In addition to screening for positive HBsAg, we will record the genotype and 
subgenotype for every patient infected with HBV, streamlining the process of determining the 
most effective treatment for each patient. Following the health fair event, we hope to provide 
care and hepatologist referrals to HBV patients who would otherwise go undiagnosed. We 
believe that the health fair will provide an unorthodox form of healthcare that is both financially 
and culturally accessible to the APIA community, and will result in more HBV patients receiving 
necessary treatment for their infection. In addition, we predict that those who attended education 
seminars at the health fair will advocate for themselves more effectively during their visits with 
their physicians. Because of the expected increase in HBV surveillance from patients who 
attended the health fair, our aim is to decrease the number of APIA patients with liver cirrhosis 
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or HCC as a result of untreated HBV infection. By following the patients over 16 years, we will 
be able to compare the long-term outcome of adequately screened patients with the current 
average outcome of Asian HBV patients.  
Unfortunately, even if a significant number of patients are successfully made aware of 
their HBV infection at the health fair, there are several reasons why these individuals may not 
receive treatment. The first is explained by unaccommodating health insurance plans: companies 
continue to discriminate against patients who are too “high-cost,” or in other words, patients with 
pre-existing conditions such as diabetes, asthma, and cancer. Although the policies in the 
Affordable Care Act prevent discrimination against pre-existing conditions including chronic 
hepatitis B, some health plans continue to discourage individuals affected by CHB from starting 
treatment by dramatically increasing copays for the two most common HBV antiviral drugs, 
Viread and Entecavir (Hepatitis B Foundation, 2016). Because of these obstacles, many CHB 
patients that need treatment are unable to receive it, due to health plans making their health 
deliberately unaffordable. Because early treatment of hepatitis B is essential in lowering the risk 
of liver cirrhosis and hepatocellular carcinoma formation, this prevention of patient care can 
ultimately have fatal consequences.  
The second, perhaps less common reason for HBV patients not receiving needed 
treatment is due to differences in cultural beliefs. Cultural practices that prevent necessary 
treatment are inherently associated with other barriers such as the inability to communicate in 
English, negative perceptions of Western medicine, and underrepresentation of APIA individuals 
among health care providers. A combination of these factors can lead to patient refusal for HBV 
medication, failure to follow up with their health provider, and miscommunication regarding the 
seriousness of their chronic disease.  
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Potential Pathways Toward Remedying the Racial Disparity in HBV Prevalence 
Adjusting CDC and AASLD Protocols 
There are several potential solutions to remedy this apparent disparity in suboptimal 
screening for HBV infection. The first is to improve on existing CDC and AASLD guidelines to 
highlight the importance of addressing HBV risk in target populations. Studies have shown that a 
significant proportion of health providers are not only unfamiliar with the AASLD guidelines for 
HBV management, but are also unaware of the effectiveness of HBV therapy in reducing risk of 
liver disease progression. In addition, many health providers fail to identify vaccine-eligible 
patients in high-risk populations, and many are also unaware that HBV infection can lead to the 
formation of HCC in the absence of liver cirrhosis, highlighting the need for further health 
education and communication between primary care physicians and liver specialists. The CDC 
and AASLD guidelines recommend that individuals born in countries with an HBsAg 
seroprevalence ≥ 2%, in addition to U.S.-born individuals not vaccinated as infants with parents 
born in these high-risk regions be screened for HBsAg and anti-HBs, but these guidelines are 
often not implemented in practice. As a first step to mend the racial disparity in HBV prevalence, 
it is essential that physicians and other health providers be trained using the AASLD guidelines 
for HBV management, and normalize the practice of adjusting the typical screening protocol to 
address the needs of higher-risk populations.  
Cultural Competence and Racial Bias in Healthcare 
As important as medical knowledge in the field of healthcare is the practice of cultural 
competence. It is a common trend for patients to pursue care from doctors with similar cultural 
backgrounds -- for example, APIA patients prefer to seek care from doctors that share their 
native language and cultural values. As studies have shown, doctors that speak an Asian 
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language and those who serve a significant proportion of APIA patients are more likely to 
optimally screen for HBV infection. The results from these studies point to the importance of 
increased cultural competence and sensitivity training among health providers, especially those 
in rural areas that have a shortage of non-Caucasian physicians. In addition to training sessions 
focusing on cultural competence, hiring translators and interpreters at every practice that 
provides health services to non-native English speakers is likely to establish more trust between 
patient and provider, and ultimately give the patient more autonomy in their own care.  
Additional Opportunities for Free Healthcare 
To continue to provide care to underserved communities in Southern California, it is 
essential to find funding for additional free clinic events for the public. We expect there to be a 
significant turnout of participants at our health fair event, because it will be specifically 
advertised to non-English speaking individuals whose needs are often dismissed by healthcare 
professionals. Free clinic events that are successfully targeted toward immigrant populations 
often are well-attended, implying the need for more attentive and accessible healthcare for 
individuals born outside the US. Overall, more opportunities for free healthcare are essential to 
remedy the racial and economic disparities in health in the US. In addition to the need for 
increased opportunities to free healthcare is the need for increased health education to 
communities that do not have the same access to medical information and treatment. The need 
for more accessible health education reaches far beyond hepatitis B and liver disease, given the 
multitude of other chronic diseases that also require constant screening early intervention for 
treatment to be successful. Chronic diseases such as cardiovascular disease, benign neoplasms, 
diabetes mellitus and others can be treatable if discovered at the right time -- this only highlights 
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the necessity of serving vulnerable communities of individuals who lack English fluency in the 
US who ultimately face the most fatal consequences of these chronic diseases.  
Shortcomings and Future Studies 
We want to acknowledge that while this study may deliver essential implications 
regarding the racial disparity in healthcare and disease in the US, there are significant 
shortcomings in its methodology. Due to the high proportion of Asian immigrants in the 
Southern California area, the study intentionally puts an emphasis on remedying the health 
disparity in individuals of Asian descent, but there are countless other communities in the 
country whose health continues to be neglected. For example, rates of hepatitis C infection and 
colorectal cancer are significantly higher in Black Americans than the national average, with 
evidence that American individuals of African descent are not only 20% more likely to have 
colorectal cancer than other racial groups, but also 40% more likely to die from it (Cancer.org, 
2020). This alarming disparity is only one of many in the US, yet racial disparities in health are 
not discussed nearly enough in medical education and provider training. Black Americans not 
only face a higher genetic risk for particular cancers, but they also face significant discrimination 
and bias in the healthcare field, in addition to obstacles to optimal healthcare due to factors such 
as lower paying jobs, minimal health insurance coverage, lack of access to healthy and 
affordable foods, and low-quality education and housing. While the methodology of this study 
does not address the significant health disparities faced by Black Americans, we hope that the 
results of the survey and longitudinal study may serve as a call to action to alter the current 
healthcare system so that it serves the entire country, and not just those with financial and racial 
privilege.   
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CONCLUSION 
Great strides have been made in the past decades in the treatment options for hepatitis B 
infection -- while paths toward the complete eradication of the virus have not yet been found, 
there are several commonly used treatments that, if used early enough in disease progression, can 
drastically minimize the risk of developing liver cirrhosis or hepatocellular carcinoma. More 
research has yet to be conducted to obtain a better understanding of the role of HBV genotypes 
and subgenotypes in developing more targeted treatment for specific racial groups. Despite our 
current ability to control disease progression with existing HBV treatments, the continuing 
research to improve the efficacy of existing HBV treatment is moot unless more efforts are 
directed toward ensuring that individuals in high-risk communities are accurately diagnosed and 
given access to affordable treatment. We hope that more health fairs similar to the one proposed 
become a more common practice, but ultimately, our goal is to find a path toward ensuring that 
all individuals in the US that are most at risk for having chronic hepatitis B infection are 
adequately screened and treated before their liver disease progresses to a stage past treatment.  
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